Neurona Therapeutics, a San Francisco-based biotechnology company, has raised another $120 million to fuel its research into cell therapies for brain diseases. Neurona plans to use the money to ...
SOUTH SAN FRANCISCO, CA--(Marketwired - December 01, 2015) - Neurona Therapeutics Inc., a biotechnology company focused on the transplantation of selected neurons to treat intractable neurological ...
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today ...
Belgian pharma company UCB (UCBJY) on Friday announced an agreement to acquire Neurona Therapeutics, a U.S.-based developer of cell therapies for neuronal diseases, for a total consideration of up to ...
Neurona Therapeutics Inc., a biotechnology company focused on the transplantation of selected neurons to treat intractable neurological diseases, today announced its launch with a $23.5 million Series ...
Hosted on MSN
UCB to purchase Neurona and NRTX-1001 for $1.15bn
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio. The deal value comprises an ...
After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's UCB is getting in on the action with a Friday acquisition potentially worth more than $1 billion. Building on its ...
ATLANTA, April 17, 2026 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it has entered into a definitive agreement under which UCB would acquire ...
Neurona Therapeutics’ epilepsy treatment could be a breakthrough for stem-cell technology. This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it ...
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological ...
NRTX-1001 is being assessed for drug-resistant mesial temporal lobe epilepsy Neurona Therapeutics has announced that it has secured $120m in funding to help advance its lead candidate, NRTX-1001, a ...
Company Combines Leaders in Fields of Neuroscience and Stem Cell Biology to Develop Cell Therapies With Broad Potential to Treat Neurological Disease SOUTH SAN FRANCISCO, CA--Neurona Therapeutics Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results